EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lack of Pharmacokinetic Drug–Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs

Kelong Han, Amir S Youssef, Mindy Magee, Steve Hood, Helen Tracey, Jesse Kwoh, Dickens Theodore, Melanie Paff, Ahmed Nader

Clinical Pharmacology in Drug Development · 2025-04 · 14 (4) · 281-291

DOI: 10.1002/cpdd.1518 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 14.02.2025. Verfasst von Kelong Han und 8 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Clinical Pharmacology Modeling and Simulation, Collegeville, Pennsylvania, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Guanine, Hepatitis B, Chronic, Pyrimidines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bepirovirsen is an antisense oligonucleotide currently in Phase 3 development to treat chronic hepatitis B virus (HBV) infection. Given the importance of coadministration of bepirovirsen and standard‐of‐care nucleos(t)ide analogs (NAs), we evaluated drug–drug interactions (DDIs) between bepirovirsen, entecavir (ETV), and tenofovir (TFV) using in vitro and clinical data obtained through innovative study design and sampling strategy. Static models employing in vitro data indicated that bepirovirsen is not a direct inhibitor or inducer of most drug‐metabolizing enzymes or an inhibitor or substrate of drug transporters and poses no clinical DDI risk against NAs. Bepirovirsen plasma pharmacokinetic parameters and concentration–time profiles in patients with chronic HBV in the CS3 study (NCT02981602) were similar with or without ETV or TFV coadministration, indicating no effect of NA coadministration on bepirovirsen pharmacokinetics. In patients with chronic HBV receiving both bepirovirsen and ETV or TFV in the B‐Clear study (NCT04449029), NA plasma concentrations and pharmacokinetic parameters were similar to those published without bepirovirsen coadministration, suggesting no effect of bepirovirsen coadministration on NA pharmacokinetics. This analysis demonstrated no DDI potential between bepirovirsen and NAs, suggesting that dedicated clinical DDI studies are not required. Bepirovirsen is currently being evaluated in Phase 3 studies in combination with NA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsGuanineHepatitis B, ChronicPyrimidinesTenofovirAdultFemaleHumansMaleMiddle AgedDrug Interactions

Stichwörter der Autor:innen

bepirovirsenchronic hepatitis Bdrug–drug interactionnucleos(t)ide analogspharmacokinetics

Substanzen

Antiviral AgentsentecavirGuaninePyrimidinesTenofovir

Autor:innen und Institutionen

  • GSK, Clinical Pharmacology Modeling and Simulation, Collegeville, Pennsylvania, USA.
  • GSK, DMPK - Disposition & Biotransformation, Stevenage, Hertfordshire, UK.
  • GSK, PBPK Modelling, DMPK, Preclinical Sciences, Research Technologies, R&D, Stevenage, Hertfordshire, UK.
  • Ionis Pharmaceuticals Inc., Carlsbad, California, USA.
  • GSK, Clinical Research, Hepatology, Durham, North Carolina, USA.
  • GSK, Development Medicine, Collegeville, Pennsylvania, USA.

Zitieren

APA

Han, K., Youssef, A. S., Magee, M., Hood, S., Tracey, H., Kwoh, J., Theodore, D., Paff, M., & Nader, A. (2025). Lack of Pharmacokinetic Drug–Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs. Clinical Pharmacology in Drug Development, 14(4), 281-291. https://doi.org/10.1002/cpdd.1518

Vancouver

Han K, Youssef AS, Magee M, Hood S, Tracey H, Kwoh J, et al. Lack of Pharmacokinetic Drug–Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs. Clinical Pharmacology in Drug Development. 2025;14(4):281-291. doi:10.1002/cpdd.1518

BibTeX
@article{Han2025,
  author = {Han, Kelong and Youssef, Amir S and Magee, Mindy and Hood, Steve and Tracey, Helen and Kwoh, Jesse and Theodore, Dickens and Paff, Melanie and Nader, Ahmed},
  title = {Lack of Pharmacokinetic Drug–Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  volume = {14},
  number = {4},
  pages = {281--291},
  doi = {10.1002/cpdd.1518}
}
Kostenlos starten →